Clinuvel Pharmaceuticals Valuation
Is UR9A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UR9A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UR9A (€7.85) is trading below our estimate of fair value (€62.55)
Significantly Below Fair Value: UR9A is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UR9A?
Key metric: As UR9A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is UR9A's PE Ratio? | |
|---|---|
| PE Ratio | 18.3x |
| Earnings | AU$35.64m |
| Market Cap | AU$651.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.3x |
| Enterprise Value/EBITDA | 9.5x |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does UR9A's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.2x | ||
FYB Formycon | 12.9x | 31.5% | €827.2m |
BIO3 Biotest | 15.8x | 29.3% | €1.4b |
2INV 2invest | 12.7x | n/a | €63.8m |
PSG PharmaSGP Holding | 15.4x | 13.9% | €280.6m |
UR9A Clinuvel Pharmaceuticals | 18.3x | 26.2% | €651.3m |
Price-To-Earnings vs Peers: UR9A is expensive based on its Price-To-Earnings Ratio (18.3x) compared to the peer average (14.2x).
Price to Earnings Ratio vs Industry
How does UR9A's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: UR9A is good value based on its Price-To-Earnings Ratio (18.3x) compared to the European Biotechs industry average (27x).
Price to Earnings Ratio vs Fair Ratio
What is UR9A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.3x |
| Fair PE Ratio | 16.2x |
Price-To-Earnings vs Fair Ratio: UR9A is expensive based on its Price-To-Earnings Ratio (18.3x) compared to the estimated Fair Price-To-Earnings Ratio (16.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Fortrea Holdings
US$1.8b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.40
7D
-1.6%
1Y
-38.3%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.29
7D
-1.8%
1Y
0.2%